Spotted on
Amyl Therapeutics
Amyl Therapeutics develops a fusion protein platform designed to treat amyloid related neurodegenerative diseases including Alzheimer's and Parkinson's. The Liège based biotech closed an €8.25 million Series A extension in September 2026, bringing its total funding to €27.85 million.
TECHnicalBeep
Sponsored by:
technicalbeep.com/maps/startups/amyl-therapeutics
European ecosystem maps